Guest guest Posted July 23, 2005 Report Share Posted July 23, 2005 Trial Information Summary: Peripheral Blood Stem Cell Mobilization and Storage in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission on Imatinib. This is a study to see the safety and feasibility of harvesting peripheral blood stem cells from patients with CML in complete cytogenetic remission on Imatinib. Peripheral blood stem cells in remission can be collected, frozen and stored for future use for autologous transplantation, should the CML become resistant to Imatinib, or show signs of acceleration. Imatinib will be temporarily discontinued. Filgrastim (G-CSF) will be given to stimulate stem cells, and an apheresis catheter inserted. Up to five days of pheresis will be undertaken to get adequate numbers of stem cells. Percentage of Philadelphia chromosome will be checked pre- and post-harvest. After harvesting patients will resume Imatinib and return to the care of their primary oncologist. Study Criteria: * CML in complete cytogenetic remission as measured by bone marrow evaluation within 1 month. * On Imatinib greater than 3 months. * Age >18. * Adequate organ function for transplantation. * HIV negative. * Patients must either not be eligible or currently refusing allogeneic stem cell transplantation. * Marrow myelofibrosis < 3+. For more information, Contact: Gwen L. Nichols, M.D., Principal Investigator Columbia University Medical Center 650 W. 168th St., BB 20-08 New York, NY 10032 Telephone: 212-305-5705 Fax: 212-305-7348 Email: nichols@... Profile Page: Columbia University Medical Center, New York, NY Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.